Zilining Powder Veterinary Grade API is released as a white to off-white crystalline powder under product code ZLN-VP-220; the micronized injection-grade variant is designated ZLN-VP-220I and the air-jet-milled solid oral variant is designated ZLN-VP-220M. The material is qualified for manufacture of tablets, capsules, oral powders, granules, medicated premixes, and injectable solutions after route-specific processing. Unlike feed-grade premixes, the API contains no calcium carbonate, corncob, or vermiculite carrier; assay normalization is performed on the dried basis, and residual water content is controlled to prevent hydrolysis in moisture-sensitive granulation lines. Batch release includes high-performance liquid chromatography assay, related substances, loss on drying, heavy metals, residual solvents, microbial enumeration, and, for injection-grade lots, bacterial endotoxins. Packaging is double low-density polyethylene liners in 25 kg net fibre drums. The API is manufactured under ICH Q7 active substance GMP principles and is suitable for Type A medicated article downstream use where 21 CFR 226 applies.

What route-specific release limits apply to the crystalline API in tablets, capsules, premixes, and injections?

For each dosage route, acceptance limits are route-specific rather than a single superficial specification. The oral tablet and capsule grade permits a particle-size D90 up to 150 µm because downstream wet milling and granulation reduce segregation risk; the injection-grade lot is controlled to D90 ≤ 75 µm to allow rapid wetting and to meet subvisible particle limits after dissolution. Assay by HPLC against a reference standard uses an octadecylsilyl column 250 × 4.6 mm, 5 µm with detection at 254 nm; the acceptance window for Zilining on the dried basis is 98.5–101.5%. Related substances are controlled as any individual unspecified impurity ≤ 0.5% and total impurities ≤ 2.0%. Loss on drying is ≤ 1.0% for solid oral use, but the injection-grade powder is tightened to ≤ 0.5% to avoid hydrolysis and headspace moisture uptake in vials.

These release limits are selected to maintain compendial alignment, not to guarantee clinical efficacy in a particular target species; efficacy is established by the downstream veterinary product’s regulatory file. The injection-grade lot, in addition to the solid oral profile, is controlled for subvisible particulate matter after reconstitution and for sterility when the downstream process does not include terminal sterilization. For oral powders and premixes, microbial enumeration is the critical safety parameter because these products are administered via feed or drinking water and may be stored in farm bins at high humidity.

Particle Size and Compression Failure Thresholds in Solid Oral Dosage Forms

Laser diffraction data for three consecutive production lots show D10 4.2 µm, D50 52 µm, D90 143 µm, span 2.7, bulk density 0.46 g/mL, tapped density 0.68 g/mL, Hausner ratio 1.48, and Carr index 32%. That places the unprocessed powder at the passable-to-poor flow boundary under USP <1174>; direct compression formulations therefore require 0.5 wt% colloidal silicon dioxide or 1.0 wt% magnesium stearate to maintain die-fill consistency at press speeds above 25 rpm. The powder is not suitable for direct compression without flow aid because its low bulk density and high fine fraction produce static adhesion on tableting dies.

Tablet compression on a 16-station rotary press with 10 kN main compression and 3 kN precompression reveals capping when moisture content falls below 0.5% or when turret speed exceeds 35 rpm without prior dry granulation. The failure mode is consistent with brittle fracture and low tensile strength rather than punch sticking; replacement of direct compression with roller compaction at roll pressure 6 MPa and screen 1.0 mm restores tablet hardness to 80 N and friability below 0.8% per CPV 2020 0923. These thresholds define the processing window for tablet manufacturers: maintain water content between 0.8% and 1.0% before compression, add the lubricant no earlier than 3 min before tableting, and monitor ejection force; values above 1.8 kN indicate excessive die-wall friction. Direct compression formulations that omit roller compaction often fail friability testing at high press speeds even when the powder meets the oral particle-size specification.

For capsule filling, the same oral powder is dry-mixed with lactose monohydrate to a bulk density of 0.55 g/mL; filling on a dosator machine generates acceptable weight variation below 3.0% RSD when the powder bed depth is kept constant. Powder transfer through dilute-phase pneumatic conveying should be avoided because fines below 10 µm may blind cartridge filters and shift D90 in the dosing hopper. Where granules are required, a wet granulation endpoint of 45–55% w/w mass consistency in a high-shear mixer impeller at 400 rpm and chopper at 1500 rpm yields granules with D50 180–250 µm and residual moisture 1.5–2.0% after fluid-bed drying at 55 °C inlet air. Granulation is preferred when the API is combined with hygroscopic carriers or when tablet presses operate above 40 rpm.

When Injectable Solutions Demanding Low Endotoxin and Controlled Reconstitution Are Prepared

Zilining Powder Veterinary Grade API intended for injectable solution manufacture is lot-designated ZLN-VP-220I and requires a bacterial endotoxin level < 0.50 EU/mg by kinetic chromogenic assay per CPV 2020 1143. Reconstitution in water for injection at 25 °C under aseptic conditions should be followed by sterile filtration through a 0.22 µm polyethersulfone membrane; if the solution is terminally sterilized, the thermal exposure at 121 °C for 15 min must be validated because the API may undergo pH-dependent hydrolysis above 6.5. The solution is typically compounded at pH 4.5–6.5 using citrate or acetate buffer; phosphate buffers can precipitate if calcium or magnesium ions are present in the water system. Subvisible particulate matter after reconstitution is controlled by CPV 2020 0904 / USP <788>: not more than 6000 particles per container at ≥ 10 µm and not more than 600 particles per container at ≥ 25 µm for small-volume injections. Because this API is supplied as a dry crystalline powder, hydrolytic degradation in the packaged state is lower than a ready-to-use solution; after reconstitution, the product should be used within 24 h unless stability data support longer storage at 2–8 °C.

Published solubility data for Zilining in mixed organic-aqueous injection vehicles is limited; therefore formulation work should begin with saturation shake-flask determinations per EP 5.11 before selecting co-solvent ratios. The injection-grade powder should not be combined with strong oxidizing agents or with amine-based additives at alkaline pH because these conditions accelerate degradation of the active moiety. If the drug substance is dissolved at temperatures above 50 °C, the vessel must be blanketed with nitrogen and protected from light, and the solution must be cooled to 25 °C within 4 h to avoid thermal degradation.

Residual Solvent and Heavy Metal Control in Multi-Species Premix Dilution

Medicated premixes prepared from this API typically dilute the active substance into calcium carbonate, lactose monohydrate, or wheat middling carriers at inclusion rates from 1 kg/tonne to 10 kg/tonne depending on target species and regulatory status. Residual solvent limits follow VICH GL18; methanol is limited to 3000 ppm, acetone to 5000 ppm, and ethyl acetate to 5000 ppm. Class 1 solvents are not detected by headspace gas chromatography with flame ionization detection and a limit of quantitation of 5 ppm. Heavy metals are controlled as lead not more than 10 ppm and arsenic not more than 2 ppm by CPV 2020 0821 Method II and 0822, respectively. These limits are tighter than those commonly accepted for technical-grade material and are intended to avoid accumulation in target tissues after oral administration in food-producing species. The powdered API should not be mixed with acidic or alkaline premix carriers that alter local pH beyond 4.0–8.0 unless full stability data are available.

Compared with a ready-to-use injectable solution, Zilining Powder Veterinary Grade API reduces hydrolytic degradation during storage but shifts the burden of aseptic processing to the downstream manufacturer. Compared with feed-grade premix, the API allows precise dose titration, reduces carrier-related microbial load, and avoids the analytical interference of carrier-derived pigments and sugars. However, the API is not intended for direct administration without dilution; it must be formulated into a finished dosage form or medicated premix according to the target species label.

Batch-to-batch variability in particle size D90 observed across 5 consecutive production lots ranged from 86 µm to 143 µm, which is acceptable for solid oral dosage forms after wet granulation but too broad for direct injection reconstitution without pre-filtration. Therefore, injection-grade material is air-jet milled to D90 ≤ 75 µm and then vacuum-dried at 45 °C for 6 h to reduce solvent and moisture below the tightened loss-on-drying criterion. During that milling step, the crystalline habit is retained; X-ray powder diffraction indicates no polymorph conversion when the inlet air temperature is maintained below 50 °C. Exceeding 50 °C during micronization may increase the amorphous fraction, which in turn raises hygroscopicity and reduces reconstitution clarity. This is a critical threshold for injectable grade manufacture.

For solution dosage forms used in drinking water, the API should be pre-dispersed in 10 volumes of water at 30–35 °C with gentle agitation; high-shear mixing above 1000 rpm can entrain air and generate foam that slows transfer through 0.22 µm filters. Solutions with final concentration above 5 mg/mL may require pH adjustment with 0.1 M citric acid to remain clear; precipitation at the proportioner nozzle indicates that hardness ions in the dilution water exceed 200 mg/L as calcium carbonate and should be treated with a chelating agent. These operational boundaries apply to field-use preparation and should be validated with the specific water quality on each farm.

Storage at 25 °C and 60% relative humidity in sealed aluminum laminate with desiccant has been used to maintain retest attributes for 36 months. Protect from light and moisture; do not repackage into unlined paper sacks. The retest interval is not a shelf-life extension for finished veterinary products; downstream regulatory stability protocols remain the responsibility of the finished dosage manufacturer.